Sugi Predict

Sugi Predict / Compounds / SCHEMBL978536

SCHEMBL978536

SCHEMBL978536

CN1CCOC[C@@H]1C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CNR2 P34972 2/20 0.41
▸ FKBP1A P62942 1/20 0.39
▸ CA12 O43570 3/20 0.39
▸ CA1 P00915 3/20 0.39
▸ CA9 Q16790 3/20 0.39
▸ CA2 P00918 2/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ GLA P06280 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ TDP1 Q9NUW8 1/20 0.33
▸ MMP1 P03956 2/20 0.32
▸ MMP3 P08254 2/20 0.32
▸ MMP8 P22894 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.31
▸ MMP13 P45452 1/20 0.31
▸ PDCD1 Q15116 1/20 0.31
▸ CD274 Q9NZQ7 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3138562 1.00 CNR2 (0.41) CNR2FKBP1ACA12CA1CA9
SCHEMBL18612 1.00 CNR2 (0.41) CNR2FKBP1ACA12CA1CA9
Hydrochloric Acid SCHEMBL186334 0.98 CNR2 (0.40) CNR2FKBP1ACA12CA1CA9
Hydrochloric Acid SCHEMBL23211020 0.98 CNR2 (0.40) CNR2FKBP1ACA12CA1CA9
SCHEMBL27797009 0.85 CA12 (0.40) CNR2FKBP1ACA12CA1CA9
SCHEMBL14569608 0.83 SMN1; SMN2 (0.39) CNR2FKBP1ACA12CA1CA9
SCHEMBL4471485 0.83 SMN1; SMN2 (0.39) CNR2FKBP1ACA12CA1CA9
SCHEMBL4471494 0.83 SMN1; SMN2 (0.39) CNR2FKBP1ACA12CA1CA9
SCHEMBL16160604 0.82 CNR2 (0.38) CNR2FKBP1ACA12CA1CA9
SCHEMBL3939459 0.82 CNR2 (0.38) CNR2FKBP1ACA12CA1CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250057852-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION 2025-02-20 — — US disclosed
US-12083124-B2 Bicyclic heterocycles as FGFR inhibitors INCYTE CORPORATION (US) 2024-09-10 — — US disclosed
US-20230365594-A1 THIENOPYRROLE COMPOUNDS GILEAD SCIENCES, INC. 2023-11-16 — — US disclosed
US-20230338389-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION 2023-10-26 — — US disclosed
US-11661431-B2 Thienopyrrole compounds GILEAD SCIENCES, INC. (US) 2023-05-30 — — US disclosed
CN-115835908-A Bicyclic heterocycles as FGFR inhibitors 因赛特公司 2023-03-21 — — CN disclosed
US-11607416-B2 Bicyclic heterocycles as FGFR inhibitors INCYTE CORPORATION (US) 2023-03-21 — — US disclosed
US-20220389034-A1 THIENOPYRROLE COMPOUNDS GILEAD SCIENCES, INC. 2022-12-08 — — US disclosed
EP-4045151-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS Incyte Corporation (US) 2022-08-24 — — EP disclosed
WO-2021076602-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION (US) 2021-04-22 — — WO disclosed
US-20210106588-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION 2021-04-15 — — US disclosed
WO-2020011246-A1 BENZENE RING-CONTAINING COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 广州丹康医药生物有限公司 2020-01-16 — — WO disclosed
WO-2020001592-A1 DIHYDROPYRIMIDINE DERIVATIVES AND USE THEREOF 河南天晟泰丰医药科技有限公司 2020-01-02 — — WO disclosed
US-9340540-B2 TYK2 inhibitors and uses thereof NIMBUS LAKSHMI, INC. (US) 2016-05-17 — — US disclosed
US-20110021516-A1 MONOCYCLIC CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP (US) 2011-01-27 — — US disclosed
EP-2271346-A2 MONOCYCLIC CGRP RECEPTOR ANTAGONISTS Merck Sharp & Dohme Corp. (US) 2011-01-12 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365594-A1 THIENOPYRROLE COMPOUNDS SSB, TPMT, LCP2 CNR2 422/4885FKBP1A 983/4885CA12 4338/4885
US-12083124-B2 Bicyclic heterocycles as FGFR inhibitors FGFR1, FGFR3, FGFR2 CNR2 1555/4885FKBP1A 382/4885CA12 4316/4885
US-20110021516-A1 MONOCYCLIC CGRP RECEPTOR ANTAGONISTS CCKAR, CALCRL, CCKBR CNR2 46/4885FKBP1A 2865/4885CA12 3828/4885
US-20210106588-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS FGFR1, FGFR3, FGFR2 CNR2 1555/4885FKBP1A 382/4885CA12 4316/4885
US-20250057852-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS FGFR1, FGFR3, FGFR2 CNR2 1555/4885FKBP1A 382/4885CA12 4316/4885
US-11661431-B2 Thienopyrrole compounds SSB, TPMT, LCP2 CNR2 422/4885FKBP1A 983/4885CA12 4338/4885
US-11607416-B2 Bicyclic heterocycles as FGFR inhibitors FGFR1, FGFR3, FGFR2 CNR2 1555/4885FKBP1A 382/4885CA12 4316/4885
US-20220389034-A1 THIENOPYRROLE COMPOUNDS SSB, TPMT, LCP2 CNR2 422/4885FKBP1A 983/4885CA12 4338/4885
US-20230338389-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS FGFR1, FGFR3, FGFR2 CNR2 1555/4885FKBP1A 382/4885CA12 4316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.